Avitinib
- Generic Name
- Avitinib
- Indication
用于表皮生长因子受体(EGFR)突变或T790M耐药突变的局部晚期或转移性非小细胞肺癌。
China's Biopharmaceutical Sector Achieves Record Technology Exports and FDA Approvals
• Chinese pharmaceutical companies saw technology exports nearly double in 2023, reaching a record high of 80 cases, signaling growing global influence.
• FDA approved Junshi Biosciences' Toripalimab for nasopharyngeal cancer and Bio-Thera Solutions' Avitinib, highlighting recognition of Chinese therapies.
• Multinational firms like Merck and Johnson & Johnson have invested billions in Chinese biotech, developing drugs like Carvykti for multiple myeloma.
• China leads in CAR-T clinical trials, accounting for 51% globally, but Korean bio companies face stagnation in technology export amounts.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath